Jubilee Platinum PLC’s (LON:JLP) Hernic chrome and platinum project is operating at full production rate.
The tailings project in South Africa is now processing 1,900 tonnes each day of chrome and platinum containing feed material, which equates to around 55,000 tonnes per month.
One of the early movers was ANGLE PLC (LON:AGL), the med-tech firm whose liquid biopsy may lead to a breakthrough in prostate cancer. The stock shot up 20% on the news.
Driver safety technology leader Seeing Machines PLC (LON:SEE) has secured its first UK multi-year services contract for its Guardian system solution with FreshLinc, the chilled products delivery specialist.
PCG Entertainment Plc (LON:PCGE) has received an Employment Tribunal claim form and Statement of Claim made by Nick Bryant, its former chief executive. The company will be taking legal advice.
A growing global demand for high-quality rubies has helped Gemfields PLC (LON:GEM) to generate record revenues at the latest auction of gemstones from its Montepuez ruby mine in Mozambique. Gemfields sold US$54.8mln worth of the red-coloured gems at the auction; which was held in Singapore and is the second and final ruby auction this year.
Having placed an order for 100,000 capsules of OptiBiotix Health plc's (LON:OPTI) cholesterol-reducing LP-LDL strain back in late April, German distributor HLH has entered into a three-year commercialisation agreement with the Aim-listed firm.
AIM-listed ValiRx Plc (LON:VAL) said recruitment has concluded for an early-phase study of VAL401, a potential treatment for non-small cell lung cancer. VAL-401 is being developed jointly by ValiRx and Tangent Reprofiling as part of the pair’s ValiSeek collaboration.
Asiamet Resources Limited (LON:ARS) said the infill and expansion drilling on its BKM copper project in Indonesia has met and some cases exceeded expectations. The stand-out result came from the BKM058 Zone where twin drill holes confirmed the existence of high-grade, near-surface mineralisation.
Glyn Edwards, chief executive officer of Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT), is to speak at a New York life sciences conference this month. The boss of the dual-listed drug discovery and development company, which is focused on advancing therapies for Duchenne muscular dystrophy (DMD) and Clostridium difficile infection, will participate in a DMD pipeline panel discussion at the JMP Securities Life Sciences Conference on 21 June 2017.